Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer
Frontiers in Oncology · 14.07.2026 · 16
DOI: 10.3389/fonc.2026.1829333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 14.07.2026. Verfasst von Xianwei Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Affiliated Hospital of Guizhou Medical University, Guiyang, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study aimed to develop and validate a nomogram integrating multimodal imaging and clinical features for the preoperative prediction of human epidermal growth factor receptor 2 (HER2) expression status in patients with invasive breast cancer.
Methods
A total of 204 patients with pathologically confirmed breast cancer who underwent preoperative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and mammography (MG) were retrospectively enrolled. Patients were randomly divided into training and test sets in a 7:3 ratio. Pearson correlation coefficient (PCC) combined with recursive feature elimination (RFE) was used to select optimal radiomics features. Three binary classification tasks were constructed (Model_1: HER2-Positive vs. HER2-Zero; Model_2: HER2-Positive vs. HER2-Low; Model_3: HER2-Low vs. HER2-Zero), each containing three sub-models based on MG, DCE-MRI, and their combination. The optimal radiomics model for each task was selected and integrated with independent clinicopathological factors to establish a clinical-radiomics nomogram.
Results
The combined radiomics model achieved the best performance for Model_1 and Model_2, with area under the curve (AUC) values of 0.742 (95% confidence interval [CI]: 0.624–0.860) and 0.823 (95% CI: 0.749–0.897) in the training set, and 0.718 (95% CI: 0.594–0.842) and 0.778 (95% CI: 0.696–0.861) in the validation set, respectively. Corresponding nomograms were subsequently constructed incorporating independent clinical predictors. For Model_3, the single DCE-MRI model demonstrated optimal performance (training AUC = 0.831, 95% CI: 0.747–0.916; validation AUC = 0.745, 95% CI: 0.640–0.850). However, no nomogram was developed due to the absence of significant clinicopathological features (p > 0.05).
Conclusion
The multimodal radiomics-based nomogram, integrating imaging features and clinical factors, provides a promising non-invasive quantitative tool for preoperative evaluation of HER2 expression status in breast cancer, offering significant potential for clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- The People's Hospital of Qixingguan, Bijie, China.
- Dushan county People's Hospital, Qiannan Buyi and Miao Autonomous Prefecture, Duyun, China.
- Department of Radiology, Guizhou Hospital of The First Affiliated Hospital of Sun Yat-sen University (FAH-SYSU), Guiyang, China.
Zitieren
APA
Yang, X., Liu, X., Wan, S., Luo, Y., Shen, M., & Liao, X. (2026). Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1829333
Vancouver
Yang X, Liu X, Wan S, Luo Y, Shen M, Liao X. Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1829333
BibTeX
@article{Yang2026,
author = {Yang, Xianwei and Liu, Xiaoling and Wan, Shenghong and Luo, Yilin and Shen, Mengjun and Liao, Xin},
title = {Development and validation of a multimodality radiomics-based nomogram for predicting HER2 expression status in invasive breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1829333}
}
EUVIMED